Score Breakdown
Decent.
Natera is a high-quality molecular diagnostics franchise with a dominant position in NIPT and a rapidly scaling MRD business (Signatera) that has genuine clinical differentiation backed by NEJM-published data. The company is inflecting toward cash flow positivity, but the stock at $193 and 11.9x TTM revenue prices in near-perfect execution for years. Critical concerns include: (1) ~10% annual dilution from SBC that erodes per-share value; (2) $292.5M unaccrued legal verdict creating binary downside risk; (3) revenue quality questions from $135M+ annual prior-period 'true-ups'; (4) aggressive insider selling; and (5) a valuation that requires 48%+ revenue CAGR with zero dilution to deliver 10% returns at current multiples. The business is excellent but the stock is priced for it and then some.
Paying for a dream.
Major red flags in SEC filings.
Slow bleed.
Execs cashing out.
Cash flow positive.
Bears aren't interested.
Decent.
🐻 Why Bears Hate It
The bear case centers on a 'priced-to-perfection' valuation and persistent unprofitability despite massive revenue growth. Skeptics point to a 2025 net margin of -14.61% and a return on equity of -25.07%, suggesting that scaling has yet to yield sustainable net profits. Furthermore, bears argue that as more commercial payers provide coverage, in-network pricing reductions will lead to margin erosion. High operating expenses, which grew 44.6% in 2025 to $1.8 billion, continue to outpace the path to GAAP profitability (Kavout, 2026; Investing.com, 2026).
🔍 What's In The SEC Filings
The company faces a significant existential threat from unaccrued legal liabilities and relies heavily on subjective revenue 'true-ups' to mask ongoing operational losses.
Extreme Under-accrual for Major Legal Verdict
“In November 2024, after trial, the jury returned a verdict finding the Company liable for false advertising and found damages of $292.5 million... the aggregate accrual for legal contingencies that are probable and reasonably estimable is approximately $40.8 million.”
Management is excluding a $292.5 million jury verdict from its liabilities by claiming it is not 'probable' or 'estimable' despite the verdict being rendered, creating a massive off-balance sheet risk.
Capital Injection into Founder-Controlled Entity
“Matthew Rabinowitz, the Company’s executive chairman and co-founder, is the chairman of the board and founder of MyOme... the Company... commits the Company to invest an additional $10.0 million in MyOme by January 2026.”
Natera is using corporate cash to fund MyOme, a private entity where Natera's Executive Chairman, Co-Founder, and Chief Legal Officer hold significant personal equity or board seats, presenting a high risk of value transfer from public shareholders to insiders.
Aggressive Revenue 'True-Ups' From Prior Periods
“During the nine months ended September 30, 2025 and 2024, the Company increased revenue by a net of $134.7 million and $108.1 million, respectively, for changes in estimate that increased revenue for tests delivered in prior periods.”
The company relies on 'changes in estimate' to boost current period revenue. If these estimates are consistently adjusted upward, it suggests either poor initial modeling or a 'cookie jar' reserve approach to meeting earnings targets.
Excessive Stock-Based Compensation Relative to Losses
“Total stock-based compensation expense recorded... for the nine months ended September 30, 2025 [was] $261.8 million.”
SBC exceeds the total net loss for the period ($255.4 million), meaning the company is effectively paying its employees more in equity value than its entire net loss, leading to massive continuous dilution of existing shareholders.
The intrinsic value should be immediately discounted by at least $250 million to reflect the unaccrued portion of the Guardant judgment. Furthermore, 8% of the nine-month revenue should be treated as non-recurring due to its nature as a prior-period estimate adjustment.
CFO Mike Brophy and Director Roy Baynes entered new 10b5-1 trading plans in Q3 2025, suggesting a coordinated effort to exit positions despite the 'growth' narrative.